Anti-CXCR4 antibodies and antibody-drug conjugates

Patent metadata

Field	Value
Publication number	US-10144781-B2
Application number	US-201715610417-A
Country	US
Kind code	B2
Filing date	May 31, 2017
Priority date	Aug 2, 2013
Publication date	Dec 4, 2018
Grant date	Dec 4, 2018

Abstract

The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.

First claim

It is claimed:

1. An isolated polynucleotide comprising a nucleotide sequence encoding an antibody, or an antigen binding fragment thereof, that binds to chemokine receptor 4 (CXCR4) and comprises:
a) a heavy chain variable (VH) region comprising (i) a VH CDR1 comprising SEQ ID NO:107, 113, or 114; (ii) a VH CDR2 comprising SEQ ID NO: 162 or 128; and (iii) a VH CDR3 comprising SEQ ID NO: 112; and;
b) a light chain variable region (VL) region comprising (i) a VL CDR1 comprising SEQ ID NO: 144; (ii) a VL CDR2 comprising 145; and (iii) a VL CDR3 comprising SEQ ID NO: 139.

2. A vector comprising the polynucleotide of claim 1 .

3. An isolated host cell that recombinantly produces the antibody or antigen binding fragment thereof of claim 1 .

4. A method of producing an antibody or antigen binding fragment thereof, comprising culturing the host cell of claim 3 under conditions that result in production of the antibody or antigen binding fragment thereof, and isolating the antibody or antigen binding fragment thereof from the host cell or culture medium.

Assignees

• Pfizer

Inventors

• Liu Shu-Hui
• Pernasetti Flavia Mercer
• Ho Wei-Hsien

Classifications

• A61P35/04

  specific for metastasis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title